Tobramycin Clinical Trials

Size	Price	Qty
50mg	USD 147
1g	USD 670

Clinical Trials

Numerous clinical trials spanning Phase 1 through Phase 4 evaluate tobramycin across diverse therapeutic indications, encompassing recruiting, completed, and terminated protocols. Primary conditions under evaluation include cystic fibrosis lung disease, *Pseudomonas aeruginosa* respiratory infections, open fracture surgical site infections, prosthetic joint infections, and pharmacokinetics during chronic renal dialysis, with specific focus on aerosolized formulations and prophylactic local applications. These investigations are sponsored by commercial entities and academic medical centers, including Respirion Pharmaceuticals, Massachusetts General Hospital, and Washington University School of Medicine.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05361941	RECRUITING	Periprosthetic Joint Infections	Elute, Inc.	2023-08-31
NCT05169229	RECRUITING	Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection; Prosthetic Joint Infection	University Hospital, Linkoeping	2022-04-01	PHASE2
NCT04678154	RECRUITING	Post Operative Surgical Site Infection	Major Extremity Trauma Research Consortium	2021-05-07	PHASE3
NCT04964947	ACTIVE_NOT_RECRUITING	Wound Infection; Fractures, Open; Surgical Site Infection	Massachusetts General Hospital	2022-01-10	PHASE3
NCT06016088	COMPLETED	Cystic Fibrosis Lung; Respiratory Infections, Recurrent, Chronic; Pseudomonas Aeruginosa	Respirion Pharmaceuticals Pty Ltd	2024-04-01	PHASE1; PHASE2
NCT06093191	COMPLETED	Bronchiectasis Adult; Pseudomonas Aeruginosa Infection	Jin-Fu Xu	2023-10-18	PHASE4
NCT05849090	COMPLETED	Infections	University of Utah	2023-03-27	EARLY_PHASE1
NCT07332936	COMPLETED	Symptomatic Irreversible Pulpitis; Postoperative Endodontic Pain Following Emergency Root Canal Treatment	Umm Al-Qura University	2023-07-01
NCT05607030	COMPLETED	Prosthetic-joint Infection	Osteal Therapeutics, Inc.	2023-01-23	PHASE2
NCT06404541	UNKNOWN	Ocular Surface Disease; Dry Eye Syndromes	Kasr El Aini Hospital	2024-01-10	PHASE4
NCT06016088	Recruiting	Cystic Fibrosis Lung\|Respiratory Infections Recurrent Chronic\|Pseudomonas Aeruginosa	Respirion Pharmaceuticals Pty Ltd	2024-04-01	Phase 1\|Phase 2
NCT04560179	COMPLETED	Bronchopulmonary Dysplasia	Erik Allen Jensen	2022-03-22	PHASE1
NCT05429671	COMPLETED	Total Knee Arthoplasty	Rothman Institute Orthopaedics	2022-06-20	PHASE3
NCT04872400	COMPLETED	Fractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone; Extremity Fracture Lower; Extremity Fractures Upper	University of Colorado, Denver	2021-06-14	PHASE4
NCT02819856	COMPLETED	Ototoxicity	Sound Pharmaceuticals, Incorporated	2017-07-21	PHASE2
NCT04662632	COMPLETED	Prosthetic Joint Infection	Osteal Therapeutics, Inc.	2021-11-01	PHASE2
NCT05076955	UNKNOWN	Diabetic Foot Ulcer	University of Mississippi Medical Center	2021-03-31	EARLY_PHASE1
NCT05169229	Recruiting	Arthroplasty Replacement Hip\|Osteoarthritis Hip\|Antibiotic Resistant Infection\|Prosthetic Joint Infection	University Hospital Linkoeping\|Region Östergötland\|The Swedish Research Council	2022-04-01	Phase 2\|Phase 3
NCT04964947	Recruiting	Wound Infection\|Fractures Open\|Surgical Site Infection	Massachusetts General Hospital\|United States Department of Defense	2022-01-10	Phase 3
NCT05353101	COMPLETED	Vernal Keratoconjunctivitis; Cyclosporine 0.05% Eye Drops	Second Affiliated Hospital of Nanchang University	2020-07-01	PHASE1
NCT03715322	UNKNOWN	Bronchiectasis Adult; Pseudomonas Infections	Guangzhou Institute of Respiratory Disease	2018-10-26	PHASE3
NCT03673956	COMPLETED	Chronic Rhinosinusitis (Diagnosis)	Mayo Clinic	2018-09-26	PHASE1; PHASE2
NCT02528123	COMPLETED	Myopia; Refractive Errors	London Vision Clinic	2016-04
NCT03485456	UNKNOWN	Cystic Fibrosis	University Medical Center Groningen	2019-05-29	PHASE1; PHASE2
NCT02717871	COMPLETED	Keratitis; Infectious Disease (Manifestation)	University Hospital, Geneva	2016-03	PHASE3
NCT02918409	COMPLETED	Cystic Fibrosis	National Jewish Health	2016-08-26	PHASE4
NCT03721328	COMPLETED	Prosthetic Joint Infection	Osteal Therapeutics, Inc.	2018-10-26	PHASE2
NCT04297631	COMPLETED	Antibotics in Cementless Knees	Washington University School of Medicine	2020-02-14	PHASE4
NCT02440828	COMPLETED	Ventilator Associated Pneumonia (VAP)	Erasmus Medical Center	2015-03	PHASE4
NCT02677701	COMPLETED	Cystic Fibrosis	Seattle Children's Hospital	2016-10-21	PHASE4
NCT04297631	Completed	Antibotics in Cementless Knees	Washington University School of Medicine	2020-02-14	Phase 4
NCT03066453	TERMINATED	Cystic Fibrosis	University Hospital, Lille	2017-06-13	PHASE3
NCT03904836	COMPLETED	Renal Dialysis; Renal Failure, Chronic	Maisonneuve-Rosemont Hospital	2019-01-31	PHASE1
NCT02657473	COMPLETED	Non-CF Bronchiectasis	Medical Center Alkmaar	2016-08-13	PHASE2; PHASE3
NCT02873806	COMPLETED	Open-angle Glaucoma	Glaukos Corporation	2013-03	PHASE4
NCT03928522	COMPLETED	Total Knee Replacement	Washington University School of Medicine	2019-01-28	PHASE4
NCT03975374	UNKNOWN	Blepharo Conjunctivitis	Sutphin Drugs	2019-06-15	EARLY_PHASE1
NCT02497365	COMPLETED	Bacterial Keratitis	McGill University Health Centre/Research Institute of the McGill University Health Centre	2015-09
NCT03308253	UNKNOWN	Surgical Site Infection	McMaster University	2018-07-16	PHASE4
NCT02712983	COMPLETED	Non-cystic Fibrosis Bronchiectasis	Novartis Pharmaceuticals	2017-02-08	PHASE2
NCT03502070	COMPLETED	Cystic Fibrosis	Mylan Inc.	2018-06-26	PHASE4
NCT03705962	TERMINATED	Fractures, Open	University of Virginia	2015-07	PHASE3
NCT03904836	Completed	Renal Dialysis\|Renal Failure Chronic	Maisonneuve-Rosemont Hospital	2019-01-31	Phase 1
NCT03739528	COMPLETED	Cataract	NTC srl	2018-09-03	PHASE3
NCT02054156	COMPLETED	Cystic Fibrosis	Bonnie Ramsey	2014-06	PHASE3
NCT02526004	COMPLETED	Cystic Fibrosis	University College Cork	2013-10-01
NCT02888730	TERMINATED	Cystic Fibrosis; Rhinosinusitis; Lung Diseases	Virginie ESCABASSE	2017-02-16	PHASE3
NCT01740947	TERMINATED	Colorectal Cancer	H. Jaap Bonjer, PhD	2013-01	PHASE4
NCT02478710	TERMINATED	Pneumonia, Ventilator-Associated	Wright State University	2015-06	PHASE4
NCT02958514	COMPLETED	Dry Eye Syndrome	Peking University Third Hospital	2016-11
NCT02489955	UNKNOWN	Cystic Fibrosis	The Leeds Teaching Hospitals NHS Trust	2015-02
NCT02212587	COMPLETED	Cystic Fibrosis; Burkholderia Cepacia Infection	Unity Health Toronto	2014-09	PHASE1
NCT02102152	UNKNOWN	Bronchiectasis With Chronic Infection With Pseudomonas Aeruginosa	Rabin Medical Center	2014-04
NCT01230593	COMPLETED	Chalazion Unspecified Eye, Unspecified Eyelid; Chalazion Left Eye, Unspecified Eyelid; Chalazion Right Eye, Unspecified Eyelid; Chalazion Both Eyes	McMaster University	2010-11
NCT03341741	COMPLETED	Cystic Fibrosis With Pulmonary Manifestations	University Hospital Tuebingen	2014-03-11	PHASE3
NCT02269969	COMPLETED	Burns; Infection	Sandra Walker	2015-03	PHASE1; PHASE2
NCT01844778	COMPLETED	Cystic Fibrosis	Novartis Pharmaceuticals	2013-08	PHASE4
NCT02734459	COMPLETED	Bilateral Cataract	Semler Research Center Pvt. Ltd.	2013-11	PHASE3
NCT01082367	COMPLETED	Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients	Novartis Pharmaceuticals	2010-04	PHASE3
NCT01570192	TERMINATED	Bacterial Pneumonia	University of Florida	2010-09	PHASE2
NCT02178540	COMPLETED	Cystic Fibrosis	Novartis Pharmaceuticals	2014-08	PHASE4
NCT01641822	COMPLETED	Cystic Fibrosis	Gilead Sciences	2012-12	PHASE3
NCT01677403	UNKNOWN	Bronchiectasis	Shandong University	2012-08	PHASE4
NCT02035488	COMPLETED	Bronchiectasis	University Medical Center Groningen	2013-10	PHASE1; PHASE2
NCT02015663	TERMINATED	Cystic Fibrosis	Novartis Pharmaceuticals	2014-01	PHASE4
NCT01775137	COMPLETED	Long-term Safety of TIP	Novartis Pharmaceuticals	2013-02	PHASE4
NCT02137161	COMPLETED	Cataract; Pseudoexfoliation Syndrome	Azienda USL Reggio Emilia - IRCCS	2013-11	PHASE4
NCT02207426	COMPLETED	Healthy	Pharmaero ApS	2014-07	PHASE1
NCT01519661	COMPLETED	Pulmonary Infections; Pseudomonas Aeruginosa in Cystic Fibrosis	Novartis Pharmaceuticals	2012-01	PHASE4
NCT01953367	COMPLETED	Cystic Fibrosis	Pari Pharma GmbH	2013-09	PHASE1
NCT01315678	COMPLETED	Pseudomonas Aeruginosa Infection	Insmed Incorporated	2012-02-29	PHASE3
NCT01456780	COMPLETED	Meibomian Gland Dysfunction; Posterior Blepharitis	Massachusetts Eye and Ear Infirmary	2011-08	PHASE4
NCT01560962	TERMINATED	Blepharitis	Southern California Institute for Research and Education	2012-01
NCT01270347	COMPLETED	Cystic Fibrosis	Amgen	2011-01	PHASE3
NCT01608555	COMPLETED	Cystic Fibrosis	University of Milan	2012-01	PHASE4
NCT01207245	COMPLETED	Cystic Fibrosis	University of Nottingham	2011-05	PHASE4
NCT01069705	COMPLETED	Pulmonary Infections; Pseudomonas Aeruginosa	Novartis Pharmaceuticals	2010-02-12	PHASE3
NCT00982930	COMPLETED	Pseudomonas Aeruginosa; Cystic Fibrosis	Novartis Pharmaceuticals	2009-08-12	PHASE3
NCT01337219	UNKNOWN	Cystic Fibrosis	Erempharma	2011-04	PHASE1; PHASE2
NCT01111383	COMPLETED	Cystic Fibrosis	Chiesi Farmaceutici S.p.A.	2009-09	PHASE3
NCT00918957	COMPLETED	Cystic Fibrosis	Novartis Pharmaceuticals	2009-06	PHASE3
NCT01155999	COMPLETED	Purulent Bacterial Conjunctivitis	Laboratoires Thea	2008-12	PHASE3
NCT01227915	UNKNOWN	Acute Bacterial Conjunctivitis	Azidus Brasil	2011-02	PHASE3
NCT00774072	COMPLETED	Cystic Fibrosis; Pseudomonas Aeruginosa	University of Jena	2008-10	PHASE2
NCT01044719	UNKNOWN	Cystic Fibrosis	Imperial College London	2010-01	PHASE4
NCT01400750	COMPLETED	Cystic Fibrosis	Universitaire Ziekenhuizen KU Leuven	2001-08	PHASE4
NCT00757237	COMPLETED	Cystic Fibrosis	Gilead Sciences	2008-08	PHASE3
NCT00885365	COMPLETED	Cystic Fibrosis	Chiesi Farmaceutici S.p.A.	2009-04	PHASE3
NCT00705159	COMPLETED	Conjunctivitis	Bausch & Lomb Incorporated	2008-06	PHASE4
NCT00794586	COMPLETED	Cystic Fibrosis	Gilead Sciences	2008-11	PHASE2
NCT01028027	COMPLETED	Conjunctivitis; Keratitis; Blepharitis	Bausch & Lomb Incorporated	2009-10	PHASE3
NCT01103401	COMPLETED	Cataract	Veroia General Hospital	2009-10
NCT00097773	COMPLETED	Cystic Fibrosis; Pulmonary Disease, Chronic Obstructive	Seattle Children's Hospital	2004-09	PHASE2
NCT00992355	COMPLETED	Cataract	Veroia General Hospital	2009-01
NCT00388505	COMPLETED	Cystic Fibrosis	Novartis Pharmaceuticals	2006-02	PHASE3
NCT00634192	COMPLETED	Pseudomonas Infections	Novartis	2008-02	PHASE3
NCT00420628	COMPLETED	Chalazion; Hordeolum	Bausch & Lomb Incorporated	2006-11	PHASE4
NCT00695435	COMPLETED	Dry Eye	Alcon Research	2008-06	PHASE1
NCT00823238	COMPLETED	Cystic Fibrosis	University of North Carolina, Chapel Hill	2004-07	PHASE1
NCT00576251	COMPLETED	Ocular Inflammation Associated With Blepharaconjunctivitis	Alcon Research	2007-10	PHASE3
NCT00547053	COMPLETED	Cystic Fibrosis	Boston Children's Hospital	2006-12	PHASE1
NCT00391976	COMPLETED	Cystic Fibrosis	Novartis	2003-11	PHASE3
NCT00447837	COMPLETED	Chronic Sinusitis	Naryx Pharma	2006-10	PHASE2
NCT00447577	COMPLETED	Blepharokeratoconjunctivitis	Bausch & Lomb Incorporated	2007-01	PHASE4
NCT00125346	TERMINATED	Cystic Fibrosis	Novartis	2005-09	PHASE3
NCT00362895	COMPLETED	Cataract	Alcon Research	2006-04	PHASE3
NCT00198523	COMPLETED	Eye Infections; Postoperative Complications	Bausch & Lomb Incorporated	2005-07	PHASE3
NCT00105469	COMPLETED	Bacterial Conjunctivitis	Merck Sharp & Dohme LLC	2004-07	PHASE3
NCT00532961	COMPLETED	Inflammation	Bausch & Lomb Incorporated	2005-02	PHASE4
NCT00050401	COMPLETED	Pneumonia	Pfizer	2002-07	PHASE3
NCT01559753	COMPLETED	Pneumonia Ventilator Associated	Centre Hospitalier Universitaire de Besancon	1998-01	PHASE4
NCT00257790	COMPLETED	Neutropenia; Fever; Cancer	Oslo University Hospital	2001-09	PHASE4
NCT00357773	COMPLETED	Conjunctivitis, Bacterial	Laboratoires Thea	2004-05	PHASE3
NCT01079559	WITHDRAWN	Infection; Osteoarthritis of the Knee	University of Western Ontario, Canada		PHASE3
NCT00153634	COMPLETED	Cystic Fibrosis; Chronic Bronchitis	Seattle Children's Hospital	2004-03
NCT00399945	COMPLETED	Cystic Fibrosis	Novartis	2006-05	PHASE1
NCT00006280	COMPLETED	Cystic Fibrosis	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2000-02	PHASE2
NCT00004829	COMPLETED	Cystic Fibrosis; Bacterial Infection	FDA Office of Orphan Products Development	1995-06	PHASE3
NCT00420836	COMPLETED	Cystic Fibrosis	Novartis	2006-04	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-14)

Check the Tobramycin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Tobramycin selectively binds to the bacterial 30S and 50S ribosomal subunits to block the assembly of the functional 70S complex, thereby inhibiting mRNA translation and driving rapid bactericidal cell death. This targeted disruption of bacterial protein synthesis underlies its therapeutic efficacy in combatting severe Gram-negative bacterial pathogens, particularly *Pseudomonas aeruginosa* pulmonary infections in patients with cystic fibrosis.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).